Skip to main content
. Author manuscript; available in PMC: 2024 Mar 14.
Published in final edited form as: J Allergy Clin Immunol. 2023 Nov 7;153(3):809–820. doi: 10.1016/j.jaci.2023.10.023

TABLE I.

Sample composition

Characteristic All Asthma Nonasthma P value (asthma vs nonasthma)
Sample size 1035 681 226
Mean age (y) 9.99 10.56 9.37 1.51 × 10−7
% Female 46.18 43.86 52.65 .025
% Self-reported race and ethnicity
 Black 67.25 65.20 75.22 .015
 Hispanic 24.93 27.50 16.81
 White 1.35 1.03 1.33
 Other/mixed/unknown 6.47 6.27 6.64
Traits, median (IQR)
Allergen sensitization (positive test results) 3.00 (7) 4.67 (7.67) 1.00 (3.33) 7.6 × 10−21
Total IgE concentration (IU/mL) 158 (463) 243 (655) 70 (123) 7.67 × 10−21
Blood eosinophil count (cells/mm3) 200 (300) 300 (340) 200 (200) 3.13 × 10−12
FENO (ppb) 17.00 (25.54) 19.50 (29) 8.00 (11) 2.77 × 10−16
Blood neutrophil count (cells/mm3) 2700 (1800) 2700 (1900) 2500 (1700) .01
FEV1 % predicted 95.50 (20.37) 93.70 (21.54) 100.75 (16.61) 1.20 × 10−8
FEV1/FVC (z score) −1.06 (1.60) −1.27 (1.67) −0.52 (1.20) 1.49 × 10−17
Bronchodilator response (% change from baseline) 8.40 (10.82) 9.80 (11.84) 5.60 (8.06) 7.83 × 10−14

Results are reported separately by asthma status for the combined APIC and URECA samples. The ages correspond to the year at which total IgE was measured (all other ages listed in Table E1). The medians and IQRs (in parentheses) are listed for all quantitative traits. Missing data were not included in calculations.

FVC, Forced vital capacity; FENO, fractional exhaled nitric oxide; IQR, interquartile range; IU, international units; ppb, parts per billion.